Assesment of P wave duration and dispersion in Parkinson's disease

Basit Öğe Kaydı
dc.contributor.authorKoçer, Abdulkadir
dc.contributor.authorKarakaya, Osman
dc.contributor.authorBarutçu, İrfan
dc.contributor.authorEsen, Özlem Batukan
dc.contributor.authorKargın, Ramazan
dc.contributor.authorDomaç, Füsun Mayda
dc.date.accessioned2020-04-30T22:39:41Z
dc.date.available2020-04-30T22:39:41Z
dc.date.issued2006
dc.departmentDÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.descriptionKocer, Abdulkadir/0000-0003-2866-555Xen_US
dc.descriptionWOS: 000237598100019en_US
dc.descriptionPubMed: 16600454en_US
dc.description.abstractCardiovascular disorders such as decreased heart rate variability, orthostatic hypotension, and arrhythmias have been frequently observed in Parkinson's disease (PD) patients. In this study, authors measured P wave duration and dispersion in PD patients and controls. Twenty-three consecutive patients with idiopathic PD and sex-age matched 23 control subjects were included to the study. A 12-lead surface ECG was obtained from each participant. Maximum-minimum P wave duration and P wave dispersion (PWD) were measured in both groups. Maximum P wave duration was found to be higher in PD patients than controls (117 +/- 12 vs. 105 +/- 9 ms p=0.001). Minimum P wave duration was similar in PD patients and controls (64 +/- 11 vs. 63 +/- 11 msp=0.7). PWD in PD patients was also found to be higher than those of controls (53 +/- 11 vs. 43 +/- 10 ms p=0.0001). P wave duration and PWD did not significantly differ between PD patients taking anti-parkinsonian agents from those who were not (119113 vs. 116 +/- 13 ms p=0.4 and 55 +/- 11 vs. 52 +/- 11 ms p=0.5, respectively). Moreover, when the PD patients taking anti-parkinsonian agents were excluded from the study, PD patients had still higher P wave duration and PWD compared to controls (119 +/- 11 vs. 105 +/- 9 ms p=0.004, 52 +/- 10 vs. 43 +/- 10 ms p=0.009, respectively). In conclusion, we found that P wave duration and PWD were greater in PD patients compared to control subjects. (c) 2006 Elsevier Inc. All rights reserved.en_US
dc.identifier.doi10.1016/j.pnpbp.2006.02.011en_US
dc.identifier.endpage723en_US
dc.identifier.issn0278-5846
dc.identifier.issn1878-4216
dc.identifier.issue4en_US
dc.identifier.startpage718en_US
dc.identifier.urihttps://doi.org/10.1016/j.pnpbp.2006.02.011
dc.identifier.urihttps://hdl.handle.net/20.500.12684/2799
dc.identifier.volume30en_US
dc.identifier.wosWOS:000237598100019en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherPergamon-Elsevier Science Ltden_US
dc.relation.ispartofProgress In Neuro-Psychopharmacology & Biological Psychiatryen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectatrial arrhythmiaen_US
dc.subjectParkinson's diseaseen_US
dc.subjectP wave dispersionen_US
dc.subjectP wave durationen_US
dc.titleAssesment of P wave duration and dispersion in Parkinson's diseaseen_US
dc.typeReview Articleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
2799.pdf
Boyut:
121.44 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Diğer Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu